DDInter298 DDInter448
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Carboplatin {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) downregulates {v} (Gene) YPEL5
YPEL5 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) resembles {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is associated with {v} (Gene) MET
MET {u} (Gene) is bound by {v} (Compound) Crizotinib
Carboplatin {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is associated with {v} (Gene) SOD2
SOD2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) downregulates {v} (Gene) BMPR1B
BMPR1B {u} (Gene) is bound by {v} (Compound) Crizotinib
Carboplatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Crizotinib (Compound)
Carboplatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) downregulates YPEL5 (Gene) and YPEL5 (Gene) is upregulated by Crizotinib (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) resembles lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Carboplatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is associated with MET (Gene) and MET (Gene) is bound by Crizotinib (Compound)
Carboplatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Carboplatin (Compound) treats urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is associated with SOD2 (Gene) and SOD2 (Gene) is upregulated by Crizotinib (Compound)
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) downregulates BMPR1B (Gene) and BMPR1B (Gene) is bound by Crizotinib (Compound)